Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0344307 (
analgesia
)
28,200
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Continuous femoral "3-in-1" nerve blocks are commonly used for
analgesia
after total knee arthroplasty (TKA). There are conflicting data as to whether additional sciatic blockade is needed. Our routine use of both continuous femoral (CFI) and sciatic (
CSI
) peripheral nerve blocks was changed because of concerns that sciatic blockade, and its motor consequences in particular, might obscure diagnosis of perioperative sciatic nerve injury. The revised protocol includes placing single-shot blocks and perineural catheters at both sites, but infusing local anesthetic postoperatively only in the CFI.
CSI
is reserved for patients having poorly controlled posterior knee or calf pain. A sample group of 12 patients treated with this protocol was followed. Ten of 12 patients required use of the
CSI
. Within 1 h of a 5-10 mL
CSI
bolus of 0.2% ropivacaine and beginning an infusion of the same drug at 5 mL/h, patients' median pain by verbal analog scale decreased from 7.5 to 2.0 (mean scores from 7.3 to 2.4). It was possible to maintain this level of
analgesia
until the third postoperative day when catheters were discontinued. Our experience suggests that, in most patients, adequate
analgesia
after TKA cannot be achieved with CFI alone and that the addition of
CSI
renders a significant improvement in
analgesia
.
...
PMID:Analgesia after total knee arthroplasty: is continuous sciatic blockade needed in addition to continuous femoral blockade? 1533 47
Cyclooxygenase-2 selective inhibitors (COXIB or
CSI
) have been released with a fanfare as efficacious and safer alternatives to traditional non-steroidal anti-inflammatory drugs. They purport to offer equivalent degrees of
analgesia
and an improved safety profile. COXIB currently available in Australasia are celecoxib (Celebrex), rofecoxib (Vioxx) and etoricoxib (Arcoxia). This review discusses the pharmacology of these agents and reviews recent literature regarding their effectiveness and safety. It endeavours to answer the question 'Should we be using COXIB in emergency departments in Australasia'?
...
PMID:Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing? 1523 58